Nifty
Sensex
:
:
23907.25
79117.11
557.35 (2.39%)
1961.32 (2.54%)

Pharmaceuticals & Drugs

Rating :
N/A

BSE: 543748 | NSE: AARTIPHARM

622.85
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  615.20
  •  631.60
  •  613.60
  •  615.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  146814
  •  914.94
  •  721.70
  •  394.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 5,776.50
  • 25.33
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,102.65
  • 0.47%
  • 3.11

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.10%
  • 1.98%
  • 29.45%
  • FII
  • DII
  • Others
  • 7.38%
  • 11.03%
  • 4.06%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 15.58

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 13.47

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 21.06

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
458.03
439.80
4.15%
555.49
458.36
21.19%
505.77
485.06
4.27%
448.69
471.62
-4.86%
Expenses
364.35
351.81
3.56%
459.03
373.49
22.90%
388.25
405.07
-4.15%
353.01
385.38
-8.40%
EBITDA
93.67
87.99
6.46%
96.46
84.87
13.66%
117.52
79.99
46.92%
95.68
86.24
10.95%
EBIDTM
20.45%
20.01%
17.36%
18.52%
23.24%
16.49%
21.32%
18.29%
Other Income
4.48
0.99
352.53%
2.22
0.48
362.50%
2.03
0.74
174.32%
1.39
0.29
379.31%
Interest
5.51
3.89
41.65%
4.83
4.17
15.83%
4.68
5.94
-21.21%
4.48
5.25
-14.67%
Depreciation
20.88
18.14
15.10%
20.17
17.20
17.27%
19.12
15.95
19.87%
18.77
16.25
15.51%
PBT
71.77
66.95
7.20%
73.68
63.98
15.16%
95.75
58.84
62.73%
73.82
65.03
13.52%
Tax
17.14
15.14
13.21%
18.22
16.88
7.94%
30.50
15.97
90.98%
21.06
17.34
21.45%
PAT
54.62
51.80
5.44%
55.45
47.09
17.75%
65.25
42.87
52.20%
52.76
47.69
10.63%
PATM
11.93%
11.78%
9.98%
10.27%
12.90%
8.84%
11.76%
10.11%
EPS
6.03
5.72
5.42%
6.12
5.20
17.69%
7.20
4.73
52.22%
5.82
5.26
10.65%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 24
Mar 23
Mar 22
Net Sales
1,967.98
1,852.61
1,945.23
1,199.94
Net Sales Growth
6.10%
-4.76%
62.11%
 
Cost Of Goods Sold
1,071.37
1,020.71
1,169.76
637.67
Gross Profit
896.61
831.89
775.48
562.27
GP Margin
45.56%
44.90%
39.87%
46.86%
Total Expenditure
1,564.64
1,466.56
1,603.18
994.67
Power & Fuel Cost
-
84.03
75.10
90.00
% Of Sales
-
4.54%
3.86%
7.50%
Employee Cost
-
128.03
121.32
85.20
% Of Sales
-
6.91%
6.24%
7.10%
Manufacturing Exp.
-
107.30
98.78
145.95
% Of Sales
-
5.79%
5.08%
12.16%
General & Admin Exp.
-
30.08
30.20
8.13
% Of Sales
-
1.62%
1.55%
0.68%
Selling & Distn. Exp.
-
68.88
74.83
27.38
% Of Sales
-
3.72%
3.85%
2.28%
Miscellaneous Exp.
-
27.53
33.20
0.34
% Of Sales
-
1.49%
1.71%
0.03%
EBITDA
403.33
386.05
342.05
205.27
EBITDA Margin
20.49%
20.84%
17.58%
17.11%
Other Income
10.12
4.89
2.32
4.19
Interest
19.50
17.21
21.05
11.96
Depreciation
78.94
73.24
62.54
42.12
PBT
315.02
300.49
260.77
155.38
Tax
86.92
83.59
67.28
33.13
Tax Rate
27.59%
27.82%
25.80%
21.32%
PAT
228.08
216.90
193.49
122.25
PAT before Minority Interest
228.08
216.90
193.49
122.25
Minority Interest
0.00
0.00
0.00
0.00
PAT Margin
11.59%
11.71%
9.95%
10.19%
PAT Growth
20.39%
12.10%
58.27%
 
EPS
25.17
23.94
21.36
13.49

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Shareholder's Funds
1,757.04
1,558.49
1,386.48
Share Capital
45.31
45.31
0.25
Total Reserves
1,711.50
1,513.17
1,340.91
Non-Current Liabilities
130.68
84.91
72.76
Secured Loans
0.04
0.18
0.55
Unsecured Loans
0.00
0.00
0.00
Long Term Provisions
6.06
5.36
0.00
Current Liabilities
694.39
600.62
580.67
Trade Payables
378.32
339.50
214.59
Other Current Liabilities
45.84
38.33
11.89
Short Term Borrowings
263.92
213.78
337.73
Short Term Provisions
6.31
9.01
16.46
Total Liabilities
2,582.11
2,244.02
2,039.91
Net Block
1,033.33
925.84
782.09
Gross Block
1,609.29
1,431.25
1,225.00
Accumulated Depreciation
575.96
505.41
442.90
Non Current Assets
1,236.46
1,081.02
1,011.75
Capital Work in Progress
136.92
101.87
187.37
Non Current Investment
36.78
35.52
32.23
Long Term Loans & Adv.
29.44
17.78
10.07
Other Non Current Assets
0.00
0.00
0.00
Current Assets
1,345.64
1,163.01
1,028.15
Current Investments
70.39
50.99
0.00
Inventories
642.86
602.04
475.45
Sundry Debtors
519.34
450.10
376.66
Cash & Bank
24.07
12.19
83.27
Other Current Assets
88.98
7.70
10.74
Short Term Loans & Adv.
71.97
39.98
82.03
Net Current Assets
651.25
562.38
447.48
Total Assets
2,582.10
2,244.03
2,039.90

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Cash From Operating Activity
216.35
250.12
-43.70
PBT
300.49
260.77
155.38
Adjustment
94.65
83.35
52.41
Changes in Working Capital
-121.85
-31.63
-230.36
Cash after chg. in Working capital
273.29
312.50
-22.57
Interest Paid
0.00
0.00
0.00
Tax Paid
-56.94
-62.38
-21.13
Other Direct Exp. Paid
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
Cash From Investing Activity
-214.56
-157.80
-138.74
Net Fixed Assets
-203.41
-117.58
Net Investments
-6.18
-15.61
Others
-4.97
-24.61
Cash from Financing Activity
9.72
-163.46
260.38
Net Cash Inflow / Outflow
11.51
-71.15
77.94
Opening Cash & Equivalents
12.12
83.27
5.33
Closing Cash & Equivalent
23.63
12.12
83.27

Financial Ratios

Standalone /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Book Value (Rs.)
193.85
171.97
53646.60
ROA
8.99%
9.03%
11.98%
ROE
13.08%
13.35%
18.23%
ROCE
16.75%
16.11%
19.40%
Fixed Asset Turnover
1.22
1.46
0.98
Receivable days
95.50
77.57
114.57
Inventory Days
122.63
101.09
144.62
Payable days
128.34
86.45
61.41
Cash Conversion Cycle
89.79
92.21
197.78
Total Debt/Equity
0.15
0.14
0.25
Interest Cover
18.46
13.39
13.99

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.